(Total Views: 391)
Posted On: 05/26/2021 9:36:47 PM
Post# of 145871
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: chazzledazzle #91925
You nailed it, the endpoint of treatment in this case is not a milligram dose or a serum value. Half life does not filter in, if RO drops and the drug is still present, I would try to increase serum levels till RO increases. This becomes the CLINICAL treatment, not the lap top treatment. Give flexibility to the clinician within a trial design and amazing results could be forthcoming. The endpoint is efficacy which can be measured simply by RO regardless of weight, gender lean body mass. And I am not peddling INCelldx kits, have whomever in Brazil do the study!!
Study design becomes touchy with adding a placebo blood draw and changing doses based on lab measurements, but can be done. I know if I were treating critical COVID in the ICU I would treat to max RO, and even go beyond the dose if needed since toxicity is not an issue.
Study design becomes touchy with adding a placebo blood draw and changing doses based on lab measurements, but can be done. I know if I were treating critical COVID in the ICU I would treat to max RO, and even go beyond the dose if needed since toxicity is not an issue.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)